Ascendis Orphan Status for the Treatment of Hypoparathyroidism

 –   U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for YORVIPATH in the United States for the treatment of hypoparathyroidism in adults

https://www.globenewswire.com/news-release/2024/09/11/2944863/0/en/Ascendis-Pharma-Receives-Orphan-Drug-Exclusivity-in-the-U-S-for-YORVIPATH-Palopegteriparatide-for-the-Treatment-of-Hypoparathyroidism-in-Adults.html